78 related articles for article (PubMed ID: 3698052)
41. Paclitaxel, carboplatin, and vinorelbine in the treatment of advanced non-small cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
Hainsworth JD; Burris HA; Morrissey LH; Thomas M; Erland JB; Butts JA; Joseph G; Kalman L; Greco FA
Cancer J; 2000; 6(3):151-6. PubMed ID: 10882330
[TBL] [Abstract][Full Text] [Related]
42. Phase II trial of 4'-deoxydoxorubicin in advanced non-small cell lung cancer.
Kaplan S; Sessa C; Joss R; Obrecht JP; Siegenthaler P; Cavalli F
Cancer Treat Rep; 1985 Nov; 69(11):1337-8. PubMed ID: 4092200
[No Abstract] [Full Text] [Related]
43. Bisantrene, an active new drug in the treatment of metastatic breast cancer.
Yap HY; Yap BS; Blumenschein GR; Barnes BC; Schell FC; Bodey GP
Cancer Res; 1983 Mar; 43(3):1402-4. PubMed ID: 6825109
[TBL] [Abstract][Full Text] [Related]
44. Phase II trial of postoperative adjuvant cisplatin and etoposide in patients with completely resected stage I-IIIa small cell lung cancer: the Japan Clinical Oncology Lung Cancer Study Group Trial (JCOG9101).
Tsuchiya R; Suzuki K; Ichinose Y; Watanabe Y; Yasumitsu T; Ishizuka N; Kato H
J Thorac Cardiovasc Surg; 2005 May; 129(5):977-83. PubMed ID: 15867769
[TBL] [Abstract][Full Text] [Related]
45. [Phase II study of KW 2083 [7-N-(p-hydroxyphenyl)-mitomycin C] in patients with various cancers].
Nishi I; Yokoyama T; Nakao I; Harashima S; Ohashi Y; Kanko T; Saito T
Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 1):2513-9. PubMed ID: 6508315
[TBL] [Abstract][Full Text] [Related]
46. Weekly, high-dose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the Cancer and Leukemia Group B.
Akerley W; Herndon JE; Egorin MJ; Lyss AP; Kindler HL; Savarese DM; Sherman CA; Rosen DM; Hollis D; Ratain MJ; Green MR
Cancer; 2003 May; 97(10):2480-6. PubMed ID: 12733147
[TBL] [Abstract][Full Text] [Related]
47. Phase II trial of etoposide, vincristine, and high-dose cisplatin in advanced non-small cell lung cancer.
Bertrand M; Multhauf P; Presant C; Rappaport D; Blayney DW; Carr BI; Cecchi G; Doroshow JH; Emont E; Goldberg D
Cancer Treat Rep; 1985 Nov; 69(11):1335-6. PubMed ID: 4092199
[No Abstract] [Full Text] [Related]
48. Phase II evaluation of bisantrene in refractory multiple myeloma. A Southwest Oncology Group study.
Durie BG; Crowley J; Coltman CA; Chapman RA; Balcerzk SP; Bonnet JD; Lipschitz DA; Stephens RL; Cheson BD
Invest New Drugs; 1991 Nov; 9(4):329-31. PubMed ID: 1804807
[No Abstract] [Full Text] [Related]
49. Bisantrene in advanced, hormone-resistant carcinoma of the prostate: an Illinois Cancer Council phase II study.
Vogelzang NJ; Lanzotti VJ; Muntean B; Blough RR
Invest New Drugs; 1990 Aug; 8(3):313-5. PubMed ID: 2272771
[No Abstract] [Full Text] [Related]
50. Bisantrene, biological and clinical effects.
Coltman CA; Osborne CK
Cancer Treat Rev; 1984 Dec; 11(4):285-8. PubMed ID: 6534510
[TBL] [Abstract][Full Text] [Related]
51. Phase II studies of PCNU and bisantrene in advanced renal cell carcinoma.
Elson PJ; Earhart RH; Kvols LK; Spiegel R; Keller AM; Kies MS; Davis TE; Stevens C; Gumas L; Trump DL
Cancer Treat Rep; 1987 Mar; 71(3):331-2. PubMed ID: 3815401
[No Abstract] [Full Text] [Related]
52. Phase II evaluation of aclarubicin in refractory multiple myeloma: a Southeastern Cancer Study Group Trial.
Gockerman JP; Silberman H; Bartolucci AA
Cancer Treat Rep; 1987; 71(7-8):773-4. PubMed ID: 3300970
[No Abstract] [Full Text] [Related]
53. Phase II study of fludarabine phosphate for the treatment of advanced non-small cell carcinoma of the lung: a Southwest Oncology Group Study.
Weiss GR; Crowley J; Von Hoff DD; Taylor SA; Belt RJ; Coltman CA; Hynes HE; Costanzi JJ
Cancer Treat Rep; 1986 Sep; 70(9):1123-4. PubMed ID: 2427196
[No Abstract] [Full Text] [Related]
54. Radioangiocardiogram monitoring in patients receiving bisantrene.
Myers JW; Von Hoff DD; Kuhn JG; Nusynowitz M; Benedetto AR; Pocelinko R
Am J Clin Oncol; 1984 Apr; 7(2):129-30. PubMed ID: 6702715
[TBL] [Abstract][Full Text] [Related]
55. Depression of cardiac function by bisantrene.
Artman M; Roloff JS; Olson RD; Parrish MD
South Med J; 1985 Dec; 78(12):1517-8. PubMed ID: 3865379
[TBL] [Abstract][Full Text] [Related]
56. Bisantrene hydrochloride in gastric adenocarcinoma: a Southwest Oncology Group Study.
Panettiere FJ; Jones SE; Oishi N; Eyre HJ; O'Bryan RM; Andes WA; Taylor SA; Grozea PN
Med Pediatr Oncol; 1986; 14(2):78-80. PubMed ID: 3713640
[TBL] [Abstract][Full Text] [Related]
57. Phase II study of 9-10 anthracene-dicarboxaldehyde bis(4,5-dihydro-1H-imidazol-2-yl) hydrazone dihydrochloride (CL216,942; ADAH) in patients with advanced colorectal carcinoma.
Rubin J; Kvols LK; Moertel CG; Jones AR; Hahn RG; O'Connell MJ
Am J Clin Oncol; 1983 Aug; 6(4):477-9. PubMed ID: 6869319
[TBL] [Abstract][Full Text] [Related]
58. Bisantrene solubility and skin toxicity studies: efficacy of sodium bicarbonate as a local ulceration antidote.
Dorr RT; Peng YM; Alberts DS
Invest New Drugs; 1984; 2(4):351-7. PubMed ID: 6096286
[TBL] [Abstract][Full Text] [Related]
59. A phase II trial of bisantrene (CL216,942) in refractory epithelial ovarian cancer.
Kavanagh JJ; Gershenson DM; Saul PB; Copeland LJ
Gynecol Oncol; 1986 Jan; 23(1):40-3. PubMed ID: 3943750
[TBL] [Abstract][Full Text] [Related]
60. Characterization of the pharmacokinetics of bisantrene (NSC-337766).
Kuhn JG; Ludden TM; Myers JW; Von Hoff DD
Invest New Drugs; 1983; 1(3):253-7. PubMed ID: 6678875
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
